Gene Bridges is a self-funded biotech company founded in June 2000 as a spin-off of the European Molecular Biotechnology Laboratory (EMBL). The company commercializes its patented Red/ET recombination worldwide as licenses and supplies several products for the pharmaceutical and biotech industry as well as academia. Since 2004 Gene Bridges operates from the Technologie Park in Heidelberg and provides customized in-house DNA modification of any kind. Customer benefit from over 10 year experience and already 500 completed DNA modification projects.
The team consists of highly skilled technicians and scientists with profound knowledge of molecular and microbiological techniques, mouse genetics, transgene strategies, biochemistry, metabolic engineering and industrial biotechnology.
Gene Bridges also invests in research projects to continuously develop its technology and broaden the know-how to deliver further innovations and products to the Life Science market.